#United States #Class Action #San Francisco #Corcept Therapeutics #FDA concerns

Corcept Therapeutics Faces Legal Challenges in Class Action Lawsuit

In a significant development for investors, Corcept Therapeutics Incorporated (NASDAQ: CORT) is currently entangled in a class action lawsuit filed by the Allegheny County Employees' Retirement System. The complaint, which targets the firm over alleged misstatements regarding FDA data relating to their lead drug candidate, relacorilant, raises serious concerns about the company's transparency and the accuracy of the information disseminated to shareholders.

Background of the Lawsuit

The lawsuit was initiated in the U.S. District Court for the Northern District of California, with the key filing number being 26-cv-01525. It asserts that Corcept misled investors by continuing to promote the efficacy of relacorilant despite knowing from the FDA that the clinical data was deemed insufficient for supporting a New Drug Application (NDA). The class period for those affected by this alleged misleading information spans from October 31, 2024, to December 30, 2025.

The heart of the allegations indicates a profound gap between public statements by the company and private communications reportedly made between the FDA and Corcept. Reed Kathrein, the Hagens Berman partner involved in the case, states, "The crux of the Corcept case revolves around an information gap between the company’s public assertions and what was happening behind closed doors with the FDA."

Key Allegations

The complaint outlines several core allegations. Firstly, it claims Corcept failed to disclose critical concerns raised by the FDA during pre-submission meetings held in late 2024 and early 2025. The FDA reportedly indicated on multiple occasions that the evidence presented by Corcept did not support the effectiveness of relacorilant. Despite these warnings, the company's executives continued to publicly tout Phase 3 clinical trial results, leading investors to believe in a stronger prospect for the drug.

On December 31, 2025, the fallout from this misrepresentation became apparent when Corcept disclosed receipt of a Complete Response Letter (CRL) from the FDA. This letter stated that the agency could not reach a favorable conclusion regarding the benefit-risk assessment of relacorilant due to inadequate evidentiary support. The immediate repercussions were drastic, with Corcept's stock plummeting roughly 50% in value, crashing from $70.20 to $34.80 in just a single trading day, effectively wiping out $2.5 billion in market capitalization.

Implications for Investors

Given this backdrop, Hagens Berman is urging investors who suffered losses during the class period to take action before the approaching deadline of April 21, 2026. This date marks the last opportunity for affected investors to petition the court for appointment as Lead Plaintiff in the action. The firm encourages anyone who purchased Corcept common stock during the affected period to reach out for guidance regarding their rights and the next steps they should consider.

For those looking to explore this issue more thoroughly, Hagens Berman has set up a dedicated CORT Case Page where one can find more specifics about the case and its implications. Legal representatives from the firm are on standby to assist individuals who wish to submit their losses or have inquiries regarding this class action.

Whistleblower Opportunities

Moreover, the firm advises that any individuals possessing non-public information regarding Corcept should contemplate their involvement in the investigative process or consider the SEC Whistleblower program. Under this program, whistleblowers providing original information may be eligible for rewards capped at 30 percent of any successful recovery made by the SEC as a result of their inputs.

In summary, as Corcept Therapeutics grapples with these severe allegations of misinformation and lack of transparency towards its investors, stakeholders are advised to remain vigilant and proactive to safeguard their investments from potential losses stemming from corporate misconduct. As the legal process unfolds, investors will be keen to monitor the developments closely, which may shape the future of Corcept and its credibility in the eyes of the public and regulators.

For further updates on this case, one can follow the official communications from Hagens Berman or visit their website for additional details regarding the lawsuit and ongoing investigations.

Conclusion

As this class action progresses, it raises fundamental questions about corporate ethics and the responsibility companies hold towards their investors. Investors are reminded to stay informed and exercise their rights to ensure accountability in the corporate sector.